| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Golimumab |
| Brand | Simponi® |
| Indication | For the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments. |
| Assessment Process | |
| Rapid review commissioned | 11/10/2013 |
| Rapid review completed | 31/10/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended. |